Recommendations for the use of slow-release oral morphine as opioid agonist therapy

Evidence, Guidelines and Recommendations

Bringing together published evidence and both clinical and experiential expertise, these recommendations are intended to guide prescribers in the use of slow-release oral morphine (SROM, brand name Kadian) as opioid agonist therapy (OAT).

Details

Category
Evidence, Guidelines and Recommendations
Format
PDF Document
File Size
File not found.
Downloads
22
Added
Aug 25, 2025
Tags
Psychiatry
Pain
Mental Health
Substance Use Disorders
Primary Care
Internal Medicine
Emergency Medicine

Related Resources

Canadian Guideline for Opioids for Chronic Non-Cancer Pain
The Canadian Guideline for Opioid for Chronic Non-Cancer Pain was developed in response to concerns that Canadians are the second highest users per capita of opioids in the world, while the rates of opioid prescribing and opioid-related hospital visits and deaths have been increasing rapidly.